ArticleItalian journal of pediatrics2024

Response to: 'Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered'.

Elio Novembre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.